Loading stock data…
MRNA
$45.37-0.57 (-1.24%)
Market ClosedLast close May 1
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Moderna, Inc. in the Healthcare sector is trading at $45.37. The stock is currently 24% below its 52-week high of $59.55, remaining 27.1% above its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why MRNA maintains its current momentum and trend strength. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 35) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$45.37
Potential Upside
5%
Whystock Fair Value$47.64
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus19 analysts
Hold
Mean target$42.58-6.2%
Range$21.00 – $69.00
Fundamentals
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pand...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.14B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.34
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-33.56%
Volume
Today's trading volume
10.21M
Recent News
Moderna Inc (MRNA) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Legal Challenges
Moderna Inc (MRNA) reports significant revenue growth and strategic advancements despite a substantial net loss due to litigation settlements.
Moderna, Inc. Q1 2026 Earnings Call Summary
Moby summary of Moderna, Inc.'s Q1 2026 earnings call
Moderna’s Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway.
Moderna defied expectations of a Covid-revenue slowdown on Friday as a surge in international vaccine sales underpinned its first-quarter results. Revenue more than tripled in Moderna’s latest quarter to $389 million from $108 million last year, handily beating analysts’ calls for $236.4 million. Moderna logged a $1.34 billion net loss, or $3.40 a share.
Moderna (MRNA) Q1 2026 Earnings Transcript
In the first quarter, we grew year-over-year revenues significantly to $0.4 billion, driven primarily by execution of our long-term strategic partnership in -- with the U.K. government. In the U.S., our seasonal flu vaccine mRNA-1010, was assigned a pot of August 5.
Stock Market Today, May 1: Tech Stocks Soar on Apple Earnings
Today, May 1, 2026, Apple’s earnings beat extended April’s record-setting run for major U.S. benchmarks and spotlighted tech’s dominance.